Written by the AllMyPeptides Research Team
Melanotan-2 vs PT-141: At a Glance
PT-141 (bremelanotide) is structurally derived from Melanotan-2. Both are melanocortin-receptor agonists, but they are studied for different receptor emphases and have different regulatory standing.
Research use only. Both compounds are supplied for in-vitro laboratory research. Neither is a medicine, and neither is for human or veterinary consumption, administration, or therapeutic use.
How They Differ — Receptor Focus
Melanotan-2 is a broad melanocortin agonist studied in pigmentation contexts. PT-141 is studied with emphasis on the melanocortin-4 receptor (MC4R), a central-nervous-system target. The structural relationship is close, but the research focus differs.
Regulatory Status
Melanotan-2 is not approved and authorities have warned against unlicensed products sold for human use. PT-141, as bremelanotide (Vyleesi), is FDA-approved in the US for a specific indication under medical supervision, but is not licensed for general use in the UK. Research-grade material of either is supplied for laboratory use only.
Sourcing for Research
See our individual guides and our UK legality overview. View Melanotan-2 and PT-141 product details.
Frequently Asked Questions
What is the difference between Melanotan-2 and PT-141?+
Is Melanotan-2 or PT-141 approved?+
Are they the same compound?+
Related Guides
Products discussed in this guide are for research and laboratory use only. AllMyPeptides does not condone or support misuse of any research materials. Not for human or animal consumption.